Apotex Inc. was founded in 1974, and is the largest Canadian-owned pharmaceutical company. From its two employees and 5,000-square-foot beginning, the company has grown to employ over 6,000 people in research, development, manufacturing and distribution facilities worldwide. The Canadian operations of the Apotex Group of Companies with 5,300 employees now occupy over 3.3 million square feet in Montreal, Richmond Hill, Toronto, Etobicoke, Mississauga, Brantford, Windsor, Winnipeg, London, Calgary and Vancouver. Apotex produces more than 220 generic pharmaceuticals in approximately 3,000 dosages and formats which, in Canada, are used to fill over 55 million prescriptions a year - the largest amount of any pharmaceutical company in this country. Apotex has initiated a program in cell-based therapeutics and is developing a novel tissue engineering approach to wound repair and soft tissue regeneration. ApoPharma Inc. is a member of the Innovative Drug Division of Apotex Inc. and is devoted to the development and discovery of new medicines.
Elastin Specialties is a private, entrepreneurial Ontario company focused on the development of human elastin polypeptide based materials for use in cardiovascular applications, dermal and urological implants. Dr. S. Rothstein, president, is a former research director for Pioneer Hybrid Seeds and former chair of the department of molecular biology and genetics at the University of Guelph. The director of research for the company is Dr. F. Keeley, an expert in extracellular matrix proteins. Elastin Specialties hold independent patent positions on the use of its core technology in biomaterials is working to develop new techniques and methods for producing recombinant proteins while increasing their current investment in Ontario.
matRegen Corp is a startup biomaterials company whose core business is aimed toward the development of proprietary products, within the health and life sciences market. The company is focused on the commercialization of regenerative medicine products for cardiovascular, nervous system markets and drug delivery. "SpinFX" - the company's proprietary platform technology - is an innovative technique used to produce novel structures, such as porous tubes, composites and coatings. The method is simple, scaleable and meets unmet needs within a diverse array of markets - from neurosurgical to cardiovascular to sensors. What is perhaps most compelling about SpinFX is that it can be used to create patent tubes that match the mechanical properties of soft tissue yet have the strength to withstand compression at the implant site.
Rimon Therapeutics was co-founded in 2000 by Drs. Michael May and Michael Sefton. They recognized that advanced materials are increasingly in demand to guide the regeneration of tissue, replace function and deliver drugs. The development of advanced biomaterials is a critical driver of the next age of medical products and the company’s primary scientific mission is the development of advanced therapeutic biomaterials.
Based in Toronto, Canada, Rimon Therapeutics aims to develop and market novel products in partnership with biotechnology, pharmaceutical and medical device companies.
Rimon Therapeutics is taking biomaterials science to a new level. The company is developing synthetic polymers that are bioactive, that is they act like drugs but have the physical properties of materials. These advanced materials stimulate the body to heal itself.
Ontario Research and Development Challenge Fund (ORDCF)
The Ontario Research and Development Challenge Fund (ORDCF) was introduced by the Ontario Government in 1997 as a 10-year program to promote research excellence and partnerships between business and Ontario research institutions. The fund is a partnership among four ministries of the Ontario government (Economic Development and Trade; Training, Colleges and Universities; Finance; and Agriculture and Food). The ORDCF provides for state-of-the-art research equipment and facilities, leading-edge research that benefits industry, and incentives for gifted researchers. The fund is designed to build excellent research capacity at an internationally competitive level in Ontario's research institutions (post-secondary institutions, hospitals, medical research institutes), and to find ways to have the greatest economic impact emanating from those programs of excellence. The ORDCF is also designed to support partnerships between research institutions and business.
Sunnybrook Health Sciences Centre
Transforming health care through the dedication of its more than 12,000 staff, physicians, volunteers and students, Sunnybrook is committed to discovering new treatments, ensuring the health and safety of our patients, and teaching current and future health care leaders. Program areas of excellence in cancer, cardiac, muskuloskeletal, neurosciences, perinatal and gynaecology, trauma, emergency and critial care, and veterns and community, and their affilliation with the University of Toronto places Sunnybrook at the forefront of Canada's premier academic health sciences centers.
Sunnybrook Research Institute (SRI) exemplifies research excellence and innovation. Scientists strive to understand and prevent disease, improve patient care and develop treatments that enhance and extend life. Last year, they conducted more than $80 million in research.
University of Toronto
Founded in 1827, the University of Toronto is Canada's largest and most distinguished university. Consistently ranked Canada's top research-intensive university by Maclean's magazine, the University of Toronto offers teaching programs in 17 academic divisions. Its programs are held on the historic St. George campus in downtown Toronto, on campuses in Mississauga and Scarborough and in nine fully affiliated teaching hospitals in Toronto.
Partnerships with industry, with government, with universities, and with a wide variety of organizations the world over have helped the University of Toronto become one of the world's leading research-intensive universities, conducting over $2 million of research per day.
Institute of Biomaterials and Biomedical Engineering - University of Toronto
The Institute of Biomaterials and Biomedical Engineering (IBBME) is a department within the faculties of applied science and engineering, dentistry and medicine. The institute is made up of about 35 core faculty members, of whom more than 20 are tenured/tenure stream faculty, supervising more than 150 graduate students, many in collaborative programs with other departments, and there are almost 100 undergraduate students. The institute pursues research in neural, sensory systems and rehabilitation engineering; biomaterials, tissue engineering and regenerative medicine; molecular imaging and biomedical nanotechnology; and medical devices and clinical technologies. IBBME is the leading biomedical engineering unit in Canada.
Chemical Engineering and Applied Chemistry - University of Toronto
The department of chemical engineering and applied chemistry is one of the oldest and largest departments of its kind in North America, with approximately 300 undergraduate students, 170 graduate students and 30 full-time professors. It has a rich history dating back to John Dalton of Dalton's Atomic Theory and a modern reputation based on its state-of-the-art research achievements. With its long history, the department continues to do research of a pure science or fundamental nature and its professors have established world-wide reputations in their fields for such work. Recently however, there has been a trend towards greater industrial interaction in research. Over the past seven years the department of chemical engineering has won more than $5.5 million in research funds per year and more than 120 companies have provided support for our work.
National Cancer Institute of Canada
The National Cancer Institute of Canada (NCIC) was formed in 1947 through a joint initiative of the Department of National Health and Welfare and the Canadian Cancer Society. The mission of the institute is, "to undertake and support cancer research and related programs in Canada that will lead to the reduction of the incidence, morbidity and mortality from cancer." The NCIC funds the entire spectrum of cancer research – from investigations into what causes cancer to clinical trials and studies that may help reduce cancer risk and improve the quality of life for people with cancer. This research takes place across the country and involves all types of cancer. We are grateful to the Canadian Cancer Society and The Terry Fox Foundation for providing the funds for this crucial research. This year, the institute awarded 77 new Canadian Cancer Society research grants and nine new Terry Fox Foundation research grants.
The Dana Foundation is a private philanthropic foundation with principal interests in science, health and education. Charles A. Dana, a New York State legislator, industrialist, and philanthropist, founded what is today the Dana Corporation. He was president of the Dana Foundation from 1950 to 1966 and actively shaped its programs and principles until his death in 1975. His abiding beliefs were in the capacity and responsibility of individuals to shape and advance their lives and in the singular role of philanthropy in helping them to do so.
Juvenline Diabetes Research Foundation
The Juvenile Diabetes Research Foundation International is the leading charitable funder and advocate of type 1 (juvenile) diabetes research worldwide. The mission of JDRF is to find a cure for diabetes and its complications through the support of research. Since its founding in 1970 by parents of children with type 1 diabetes, JDRF has awarded more than $1 billion to diabetes research, including more than $122 million in FY2006. More than 80% of JDRF’s expenditures directly support research and research-related education. In FY2006, the foundation funded 500 centres, grants and fellowships in 20 countries.
Materials and Manufacturing Ontario - Emerging Materials Knowledge
The Centre for Materials and Manufacturing's overriding objective is to support research and training within the materials and manufacturing sectors to maximize their impact on the sustained economic growth and well being of the province of Ontario. Like all OCE Centres, the Centre for Materials and Manufacturing fulfils this mandate within its sectors by developing relationships and connections between people and organizations in Ontario's post-secondary and industrial communities to accelerate new innovations and commercialize new advances through R&D activities. Its R&D portfolio is driven by the needs of Ontario industry, especially those where the economic impact of technology and knowledge will be the greatest.
Henrietta Banting Memorial Fund
From 1958 to 1971, Dr. Henrietta Banting held the position of director of the cancer detection clinic at Women's College Hospital, the first clinic for women of its kind in Ontario. She was also a lifelong advocate of women in the field of medicine, and urged young women to consider careers as doctors rather than nurses. Dr. Banting died of cancer at Women's College Hospital on July 26, 1976. Shortly after her death, the Henrietta Banting Breast Care Centre was established at the hospital, as well as the Henrietta Banting Memorial Fund, both in Dr. Banting's memory. The memorial fund supports lectures and projects related to the Centre. The memorial fund is used for advancement in prevention and detection of breast cancer and the education and treatment of breast cancer patients at Women's College Hospital.